DeCure's autonomous AMR AI scientist is researching a drug-repurposing hypothesis for Mycobacterium avium complex disease — screening already-approved drugs against its 1-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleMycobacterium avium complex disease maps to a 1-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for mycobacterium avium complex disease is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Molecular view
calcineurin like EF-hand protein 2 (CHP2) — CHP2 is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
Loading structure…
helix sheet iiidrag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 2BEC · 2.7 Å · ligand YTTRIUM (III) ION (YT3). Experimental structure, not a prediction.
What the evidence adds up to
Disseminated Mycobacterium avium complex infection in AIDS patients is closely associated with advanced immunosuppression and is an independent risk factor for early mortality. By 1994, the introduction of the semisynthetic macrolides clarithromycin and azithromycin had altered the previously dismal prospects for successful treatment. Rifabutin showed efficacy for prevention of disseminated disease. These developments improved the ability to combat the illness.
Despite these advances, some patients with disseminated MAC remain poorly responsive to therapy. Intolerance often limits treatment, and recrudescent bacteraemia frequently occurs. The 1988 commentary noted that there was very little solid data on how to treat these infections in the HIV-infected population. The 1994 review, while reporting rapid progress in understanding the infection, concluded that much remained to be learned about its optimal therapeutic management.
No concrete numbers for survival, response rates, or sample sizes are given in these abstracts. The evidence base at this time consisted of authoritative opinion and recent clinical studies whose specific numerical results are not reported here. The abstracts do not name any drugs other than clarithromycin, azithromycin, and rifabutin.
What is still missing is the solid data called for in 1988 — randomised controlled trials with reported response rates, survival figures, and tolerability data. Also absent is a clear strategy for patients who fail macrolide-based therapy, and a definition of which patient subgroups might benefit from which drug combinations.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
The Journal of Infectious Diseases · 1988 · 237 citations
Mycobacterium avium Complex Infection
AbstractNora from Dr. Merle A. Sande — The issues addressed in this AIDS Commentary are complex ones. Are organisms that constitute the Mycobacterium avium complex (MAC) significant pathogens in the patients infected with HIV? If they are, how should these infections in this population of patients be treated? Dr. Lowell S. Young has done exactly what we hoped our guest commentators would do — he has given his authoritative opinion in an area of AIDS about which there is very little solid data. Dr. Young is a highly visible infectious diseases clinician-scientist who has recently focused his energies on developing new therapies for MAC infections. In this commentary he addresses a number of key questions: What are the implications of isolating MAC organisms from patients with AIDS? What are the best techniques for isolating these organisms? Under what circumstances is treatment of value? What drugs appear to be most effective? Which ones look good for the future?
Current Opinion in Infectious Diseases · 1994 · 19 citations
Mycobacterium avium-intracellulare
AbstractDisseminated infection caused by the Mycobacterium avium complex is a common cause of symmptomatic illness in AIDS patients. The occurrence of disseminated M. avium complex is closely associated with advanced immunosuppression, and is an independent risk factor for early mortality. The efficacy of the new macrolides for treatment of active disease and rifabuting for prevention of desseminated M. avium complex have greatly improved our ability to combat this debilitating illness.
Canadian Journal of Infectious Diseases and Medical Microbiology · 1994 · 0 citations · open access
Advances in the Treatment of Desseminated <i>Mycobacterium avium</i> Complex in Adults with AIDS
AbstractAlthough the prospects for successful treatment of Mycobacterium avium complex (MAC) infection in AIDS recently seemed quite dismal, the introduction of the semisynthetic macrolides, clarithromycin and azithromycin, has altered this perspective. Several recent clinical studies have been key to our understanding of the successful management of these patients and are the basis of this review. Yet, some patients with disseminated MAC remain poorly responsive to therapy, intolerance often limits therapy, and recrudescent bacteremia often occurs. Though our understanding of this infection has been rapidly advanced in the past three years. much remains to be learned about its optimal therapeutic management.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
